The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
PredOmix has developed a novel blood test that can detect about 32 cancers in both men and women with 98 percent accuracy
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
Subscribe To Our Newsletter & Stay Updated
